For individuals with obesity-related health conditions such as type 2 diabetes, PCOS, high blood pressure, cardiovascular disease, or non-alcoholic fatty liver disease (NAFLD), weight management therapies such as GLP-1s can be an essential component of comprehensive treatment plans aimed at reducing disease and improving overall health
Multiple retrospective studies have confirmed that GLP-1RAs are associated with reduced risks of long-term adverse hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease or T2D and cirrhosis (208), as well as lowered risks of HCC development and hepatic decompensation in patients with T2D (175,209)
Preliminary data has been collected and showed an overall increase in the number of visible nodes on higher magnification levels, as well as an increased prevalence of V, X, and especially Y nodes with these higher levels of magnification
That does not mean progestins have no place